In a written statement from the company, it was noted that Regen-Cov’s 3rd phase trial results showed that patients with Covid-19 were 72 percent effective in the first week and 93 percent in the following weeks.
In the statement, it was stated that if Regen-Cov is applied subcutaneously, it reduces the risk of getting Covid-19 in non-infected by 81 percent.
Pointing out that Regen-Cov is an important development for high-risk groups that have not yet had the Covid-19 vaccine or the vaccine is not sufficiently effective due to weakness in the immune system, the US Food and Drug Administration (FDA) it was reported that the application would be made.
Regen-Cov is a combination of two drugs that mimic natural antibodies.
It was noted that the cocktail of Regeneron, which was conducted jointly with the US National Institute of Allergy and Infectious Diseases (NIAID) and conducted clinical trials on 1500 people, consists of a combination of two drugs designed to mimic the antibodies produced naturally by the immune system.
The drug, which was only allowed for emergency use in clinics in November 2020, was not preferred in the treatment of Covid-19 because it was given intravenously and it was time-consuming and difficult to apply.
ALSO USED IN TREATMENT OF TRUMP
Regeneron’s cocktail was also used in the treatment of former US President Donald Trump, who announced that he had caught Covid-19 on October 2, 2020.
Trump’s doctor, Sean Conley, stated that they applied Regeneron’s 8-gram “antibody cocktail” treatment to Trump at Walter Reed Military Hospital, where he was removed after the Covid-19 test was positive, and that there was no negativity as a result.